Steven Simoens1*
David Dodwell2Michael Hartevelt3Peter Lindgren4,5
Michele Pistollato6
Lisa G. Pont7
Caridad Pontes8Alexander Roediger3Antun Sablek9
Eric Van Ganse10
Qinyi Wang11
Chris Wenger12Tim Wilsdon6
Entela Xoxi13
Brian Godman14,15- 1KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium
- 2Oxford Population Health, University of Oxford, Oxford, United Kingdom
- 3Global Oncology Policy, Merck, Rahway, NJ, United States
- 4Swedish Institute for Health Economics, Lund, Sweden
- 5Health Economics, Karolinska Institute, Solna, Sweden
- 6Charles River Associates, London, United Kingdom
- 7Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia
- 8Department of Pharmacology, Therapeutics and Toxicology, Autonomous University of Barcelona, Barcelona, Spain
- 9Charles River Associates, Brussels, Belgium
- 10Pharmacoepidemiology Unit, Claude Bernard University Lyon 1, Lyon, France
- 11Charles River Associates, Cambridge, United Kingdom
- 12Aquantic AG, Zeiningen, Switzerland
- 13Postgraduate School of Health Economics and Management (ALTEMS), Catholic University of the Sacred Heart, Rome, Italy
- 14Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom
- 15Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa
A Correction on
The unexploited potential of data systems tracking medicines utilization: an opportunity to improve access to oncology combination therapies
by Simoens S, Dodwell D, Hartevelt M, Lindgren P, Pistollato M, Pont LG, Pontes C, Roediger A, Sablek A, Van Ganse E, Wang Q, Wenger C, Wilsdon T, Xoxi E and Godman B (2025). Front. Pharmacol. 16:1532022. doi: 10.3389/fphar.2025.1532022
Author Entela Xoxi was erroneously assigned to affiliation Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom. This affiliation has now been removed for author Entela Xoxi.
Author Lisa G. Pont was erroneously spelled as Lisa Pont.
The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: oncology combination therapies, individual patient-level healthcare data, utilization tracking, pricing and reimbursement, pharmaceutical policy, Europe, Australia
Citation: Simoens S, Dodwell D, Hartevelt M, Lindgren P, Pistollato M, Pont LG, Pontes C, Roediger A, Sablek A, Van Ganse E, Wang Q, Wenger C, Wilsdon T, Xoxi E and Godman B (2025) Correction: The unexploited potential of data systems tracking medicines utilization: an opportunity to improve access to oncology combination therapies. Front. Pharmacol. 16:1693232. doi: 10.3389/fphar.2025.1693232
Received: 26 August 2025; Accepted: 28 August 2025;
Published: 05 September 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Simoens, Dodwell, Hartevelt, Lindgren, Pistollato, Pont, Pontes, Roediger, Sablek, Van Ganse, Wang, Wenger, Wilsdon, Xoxi and Godman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Steven Simoens, c3RldmVuLnNpbW9lbnNAa3VsZXV2ZW4uYmU=